Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has provided an update on its clinical programs and financial results for the quarter ended June 30, 2026. The company has completed enrollment in APPROACH, its Phase 3 pivotal study evaluating HLP003 in major depressive disorder (MDD), with topline data expected in the fourth quarter of 2026. This milestone brings the company closer to potentially addressing the significant unmet need in MDD treatment, particularly for patients who do not respond adequately to existing therapies. The company is also enrolling participants in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program, and continues to roll participants into the EXTEND study, which assesses long-term safety and efficacy.
The advancement of HLP003 is crucial because it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to offer a significant improvement over current treatments. The Phase 3 program, if successful, could lead to regulatory submissions and eventually provide a new adjunctive treatment option for MDD. Additionally, Helus Pharma is progressing HLP004 for generalized anxiety disorder (GAD) following positive Phase 2 results that demonstrated statistically significant and clinically meaningful improvements from baseline. The design for the next study is expected to be completed by the end of the third quarter, positioning the company to advance another asset in its pipeline.
Financially, Helus Pharma reported cash of $166.4 million as of June 30, 2026, which is expected to fund operations into the second half of 2027. The company's quarterly net loss widened to $47.8 million, compared with $24.6 million in the same period last year, reflecting increased investment in the Phase 3 trials. Cash-based operating expenses rose to $37.5 million from $23.9 million, driven by the advancement of the APPROACH, EMBRACE, and EXTEND studies. The company also continues to advance HLP005 toward candidate selection, with a viable development candidate anticipated in the second half of 2027.
The implications of these developments are significant for the mental health treatment landscape. If HLP003 succeeds in Phase 3, it could provide a new mechanism of action for MDD, potentially offering durable improvements in symptoms. The company's focus on novel serotonergic agonists (NSAs) aims to promote neuroplasticity, which may address the underlying pathophysiology of depression and anxiety more effectively than conventional treatments. With the global burden of mental health disorders rising, the need for innovative therapies is urgent, and Helus Pharma's progress brings hope to patients and clinicians alike.
Investors and stakeholders will be watching closely as the company approaches key data readouts. The completion of enrollment in APPROACH and the ongoing EMBRACE trial are critical steps toward regulatory submission. The company's robust cash position provides a runway to achieve these milestones, but the success of the trials remains the primary driver of value. As the company continues to execute its clinical strategy, the potential for HLP003 and HLP004 to transform mental health care underscores the importance of these advancements.
For more details on Helus Pharma's recent results and pipeline, visit the full press release at https://ibn.fm/yfpOW.
